(Q43011863)

English

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.

scientific article published in August 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

8

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Jorge Eduardo Cortes

2

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Gautam Borthakur

7

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

6

object named as

Sergio Giralt

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Richard E Champlin

3

object named as

Richard Champlin

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Gabriela Rondon

5

object named as

Gabriela Rondon

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Nikolai Velev

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Dan Jones

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Marcos De Lima

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3631-3637

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25092

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25092

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

release_2fszswm3mvdhxlhx4e6y6bdm7a

1 reference

https://api.fatcat.wiki/v0/release/2fszswm3mvdhxlhx4e6y6bdm7a

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43011863&oldid=2215390178"